13F-HR/A: Johnson & Johnson Amends Q4 2025 Holdings Report

Johnson & Johnson filed an amended 13F-HR report, restating its equity holdings for the quarter ended December 31, 2025, totaling $555 million.

Summary

• Johnson & Johnson (J&J) filed an amended Form 13F-HR, designated as Amendment Number 1, which is a restatement of its previous report.
• The report covers the calendar quarter ended December 31, 2025.
• The total value of the institutional investment manager's holdings reported is $555,047,952.
• The filing lists 17 distinct equity holdings.
• Johnson & Johnson Innovation JJDC, Inc. is listed as an 'Other Included Manager' with Form 13F File Number 028-20073.
• All reported holdings indicate 'DFND' (Defined) investment discretion and shared voting authority with Johnson & Johnson Innovation JJDC, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While it's a routine disclosure and a restatement, it confirms J&J's continued strategic investments in the healthcare innovation space, which is generally a positive signal for long-term growth.

Positives

• The filing provides transparency regarding Johnson & Johnson's equity investment portfolio, primarily through its innovation arm, Johnson & Johnson Innovation JJDC, Inc.
• The substantial total value of holdings, $555,047,952, reflects significant investment activity in various companies, many of which are in the biotechnology and medical device sectors.

Negatives

• As a restatement, this amendment suggests a correction was needed for the initial filing, which could indicate administrative oversight, though the specific nature of the correction is not detailed.
• The filing does not provide context on changes from previous periods, making it difficult to assess portfolio performance or strategic shifts without comparing to the original filing.

Future Outlook

The filing is a historical disclosure of equity holdings and does not contain any forward-looking statements or guidance regarding future performance or investment strategy.

Industry Context

StockSavvy.ai notes that Johnson & Johnson's 13F filing, particularly through its JJDC innovation arm, highlights its strategic investments in emerging biotechnology and medical technology companies. This aligns with a broader industry trend where large pharmaceutical and healthcare companies leverage venture capital arms to foster innovation and gain early access to disruptive technologies, complementing their internal R&D efforts. The portfolio's composition suggests a focus on therapeutic development and medical devices, reflecting key growth areas within the healthcare sector.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of large pharmaceutical companies like Johnson & Johnson maintaining significant venture capital portfolios (e.g., through JJDC) is a standard industry strategy. Competitors such as Pfizer Ventures, Novartis Venture Fund, and Merck Global Health Innovation Fund similarly invest in early-stage companies to drive innovation and potential future pipeline assets.
• The reported total value of $555 million for 17 holdings indicates a concentrated, yet diversified, approach within the venture space, comparable to the scale of investment activities seen from similar corporate venture capital funds in the life sciences sector.

Related Party Transactions

• Johnson & Johnson Innovation JJDC, Inc. is listed as an 'Other Included Manager' and shares voting authority for all reported holdings, indicating a related party relationship and coordinated investment strategy within the Johnson & Johnson corporate structure.

Stakeholder Impact

• Shareholders: Provides transparency into a portion of Johnson & Johnson's investment portfolio, specifically its venture capital activities, which could contribute to future growth and diversification.
• Investment Professionals: Offers insights into J&J's strategic investment focus within the healthcare and biotechnology sectors, potentially signaling areas of future interest or collaboration.

Key Dates

Recommendation

This filing is an amended routine disclosure of past equity holdings and does not contain new information that would significantly alter the fundamental outlook or valuation of Johnson & Johnson. While it confirms ongoing strategic investments, it lacks forward-looking guidance or material changes to warrant a 'buy' or 'sell' recommendation based solely on this document. Investors should 'hold' and consider this information as part of a broader analysis of J&J's overall financial health and strategic direction.

Keywords

Johnson & Johnson, 13F-HR/A, Institutional Holdings, Equity Investments, Portfolio Disclosure, Biotechnology, Healthcare Investments, JJDC, SEC Filing